AstraZeneca is roundly rebuked by The Lancet in an editorial that
describes the firm's development of its new cholesterol-lowering
drug Crestor as a "triumph of marketing over science".
New bulk drug manufacturing facilities, worth a total of around
€123 million (£90 million), were officially opened this week at
AstraZeneca's Avlon Works near Bristol in the UK.
Iceland-based deCODE genetics announced this week that AstraZeneca
has entered into an agreement to purchase its RoboHTC automated
protein crystallography platform, earmarked for AstraZeneca's drug
discovery sites in Alderley...